Advertisement

Topics

Market Access Impact US [Haemophilia A] [Report Updated: 01062017] Prices from USD $5145

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

Losing share to competitors? Understanding market barriers can help close the gap



Haemophilia A treatment is a highly competitive market in the US, where half of the 8 brands we surveyed have nearly equal market share. Understanding the market barriers that prevent doctors from prescribing your brand is essential if you want to build a lasting competitive advantage.


Learn how 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A US.



Based on a survey of 100 USbased haematologists, the report covers 8 major therapies from Bayer, Bioverativ/Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire.







Top Takeaways



Barriers affect over a quarter of prescriptions: The two biggest barriers are responsible for more than a third of that impact.
The barrier effect is split evenly: Half of the surveyed brands lose share because of barriers, the other half gain.
Not all brands are widely prescribed: Most brands are prescribed by two thirds of doctors or less. However, most doctors are willing to consider brands they don't prescribe.
Barriers have the biggest impact on the middle of the market: Eliminating them would push the 4th place brand down to 6th place, and bump the 5th and 6th place brands up by one spot.
Barriers aren't a problem for all doctors all the time: For the most part, fewer than 20% of doctors experience any one barrier with a given brand.
Cost is a huge problem for one brand: Roughly 30% of doctors experience cost barriers with this brand. That's nearly 10% more than any competitor.

Insight into 8 Major Haemophilia A Drugs



Advate octocog alfa, Antihemophilic Factor [human]; Shire
Eloctate efmoroctocog alfa; Bioverativ/Biogen
Feiba AntiInhibitor Coagulant Complex; Shire
Helixate FS octocog alfa; CSL Behring
HumateP Antihemophilic Factor/von Willebrand Factor Complex [human]; CSL Behring
Kogenate FS octocog alfa; Bayer
NovoEight turoctocog alfa; Novo Nordisk
Xyntha moroctocog alfa; Pfizer

Exploring Market Access Barriers



Market Access Impact: Haemophilia A US explores key issues affecting drug manufacturers. You'll learn:



How barriers affect market access:



What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:



How many doctors prescribe your brand? How many don't, but would consider it?
Why don't doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge



We surveyed 100 USbased haematologists, chosen from the largest community of validated physicians in the world.



All respondents have:



Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with haemophilia A in total in the last month

We conducted the survey between May 2nd and 10th, 2017.



MONEY BACK GUARANTEE!


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.




About FirstWord



FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.



FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.


FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: Market Access Impact US [Haemophilia A] [Report Updated: 01062017] Prices from USD $5145

NEXT ARTICLE

More From BioPortfolio on "Market Access Impact US [Haemophilia A] [Report Updated: 01062017] Prices from USD $5145"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...